If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.65
Bid: 1.60
Ask: 1.70
Change: 0.00 (0.00%)
Spread: 0.10 (6.25%)
Open: 1.65
High: 1.90
Low: 1.65
Prev. Close: 1.65
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IB Launching an Expanded Access Program for GaM

10 Jan 2024 07:00

RNS Number : 1417Z
IQ-AI Limited
10 January 2024
 

IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics Launching an Expanded Access Program for Oral GaM

  

Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCBB: IQAIF), is launching an intermediate population cohort expanded access program (EAP) for oral gallium maltolate (GaM), subject to FDA approval. The EAP will be for brain tumor patients located throughout the United States who are unable to participate in the phase 1 clinical trial on-going at the Medical College of Wiscsonsin (MCW). The FDA's recent Fast Track Designation for GaM serves as the motivation behind this launch.

Under an EAP, also referred to as "compassionate use", the FDA works with companies to allow access to investigational products outside of a clinical trial. Patients who have limited or no viable treatment alternatives can gain access to promising treatments, ahead of regulatory approval, in attempt to fulfill an unmet clinical need.

To date, oral GaM has exhibited an excellent safety profile and promising anti-tumor efficacy. Thus far, none of the patients that have participated in the phase 1 trial have reported dose limiting toxicities. On the contrary, patients have shared experiences of enhanced quality of life, allowing many patients to engage in normal, pre-diagnosis, activities. Moreover, the agent can be taken from the comfort of their home.

"Along with providing immediate access to GaM for the potential benefit of some patients, the EAP will accelerate data obtained from a broader, real-world, patient population. This data would advance the development process on many levels including maximizing the full benefit of the Fast Track Designation. Pending FDA approval, we expect the EAP to start in Q2," said Trevor Brown, CEO of IQAI.

U.S. patients, patient-advocates, or physicians who are interested in learning more can email eap@imagingbiometrics.com. Also, Imaging Biometrics' Policy on Expanded Access Programs, and general information about the trial, can be found at www.imagingbiometrics.com/clinical-trials/.

About Imaging Biometrics® LLC IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For further information, please contact:

IQ-AI Ltd

Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRBLMFTMTTMBJI
Date   Source Headline
10th Mar 20117:00 amRNSFinal Results
20th Jan 20111:43 pmRNSAcquisition
14th Jan 20117:00 amRNSTrading Statement
17th Nov 20101:36 pmRNSAdditional Directorship for John Henwood
26th Oct 20107:00 amRNSInterim Management Statement
26th Oct 20107:00 amRNSInterim Management Statement
4th Oct 201012:25 pmRNSBlocklisting Interim Review
19th Aug 20107:00 amRNSCompletion of Acquisition of Garden Centre Online
11th Aug 20107:00 amRNSHalf Yearly Report
26th Jul 20101:56 pmRNSNotice of Results
24th May 201012:28 pmRNSAcquisition
12th May 201010:19 amRNSResult of AGM
12th May 20107:00 amRNSTrading Update
21st Apr 20101:32 pmRNSDirector/PDMR Shareholding
21st Apr 20107:00 amRNSDirector/PDMR Shareholding
20th Apr 201010:27 amRNSAdjournment of AGM
20th Apr 20109:09 amRNSReplacement Interim Management Statement
20th Apr 20107:00 amRNSInterim Management Statement
8th Apr 201011:12 amRNSDirector Update
1st Apr 201011:08 amRNSBlocklisting Interim Review
11th Mar 20107:00 amRNSFinal Results
13th Jan 20107:00 amRNSTrading Statement
19th Oct 20097:00 amRNSInterim Management Statement
15th Oct 20097:00 amRNSPlacing of Shares
1st Oct 20097:00 amRNSStrategic changes at Flying Flowers
30th Sep 20099:32 amRNSBlocklisting Interim Review
8th Sep 20093:08 pmRNSIssue of shares
31st Jul 20097:00 amRNSHalf Yearly Report
7th May 20092:23 pmRNSDirectorate Change
27th Apr 20097:00 amRNSDirector/PDMR Shareholding
22nd Apr 200910:01 amRNSAGM & Interim Management Statement
16th Apr 20099:55 amRNSDirector/PDMR Shareholding
30th Mar 20096:29 pmRNSBlocklisting Interim Review
13th Mar 20097:00 amRNSFinal Results
18th Feb 20097:00 amRNSDirectorate Change
21st Jan 20097:00 amRNSTrading Statement
10th Dec 200810:00 amRNSDirector/PDMR Shareholding
21st Nov 20087:10 amRNSOffer Talks Terminated
21st Nov 20087:00 amRNSStatement re Possible Offer
18th Nov 20088:28 amRNSEPT Disclosure
12th Nov 200810:24 amRNSEPT Disclosure with Trade Amendment
11th Nov 20088:40 amRNSEPT Disclosure
6th Nov 20088:46 amRNSEPT Disclosure
5th Nov 20089:09 amRNSEPT Disclosure
3rd Nov 20089:12 amRNSEPT Disclosure
31st Oct 20089:47 amRNSEPT Disclosure
29th Oct 20088:45 amRNSEPT Disclosure
28th Oct 20089:38 amRNSEPT Disclosure
27th Oct 20082:14 pmRNSEPT Disclosure - Replacement
27th Oct 200810:38 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.